

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 09th November, 2020

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Monday, 09th November, 2020 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Respected Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Monday 09th November, 2020 at the corporate office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) which commenced at 01:00 P.M. and concluded at 04:00 P.M. *inter-alia*, transacted the following business:

- i. Approved the Un-audited Financial Results of the company for the quarter and half year ended on 30th September, 2020 along with Statement of Assets and Liabilities as on that date and Cash Flow Statement for the half year ended on 30th September, 2020. (Copy of the same Enclosed herewith).

Furthermore, the extract of the Un-audited Financial Results would also be published in the newspapers in compliance with Regulation 47 of Listing Regulations.

- ii. Took on record the Limited Review Report for the quarter and half year ended on 30th September, 2020. (Copy of the same Enclosed herewith).


TRADING WINDOW:

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from 12th November, 2020 for all Designated Persons, their immediate relative and other connected person(s).

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,
FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD.


AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.NO.: 29371

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)


Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2020

S. No.	Particulars	Quarter ended			Half Year ended		Rs.in Lakhs
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	Year ended
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	(Audited)
I.	Revenue from Operations	1,038.14	-	171.81	1,038.14	209.56	540.03
II.	Other Income	2.06	2.01	4.05	4.07	4.06	8.02
III.	Total Income (I+II)	1,040.20	2.01	175.86	1,042.21	213.62	548.05
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	1,000.30	-	170.75	1,000.30	208.00	512.69
	Changes in inventories of:						
	Finished Goods	-	-	-	-	-	-
	Work in Progress	-	-	-	-	-	-
	Stock in Trade	-	-	-	-	-	-
	Employee Benefit Expenses	2.62	2.84	3.01	5.46	6.38	9.06
	Finance Cost	0.01	-	0.02	0.01	0.03	0.21
	Depreciation and Amortisation Expenses	0.08	0.08	0.06	0.16	0.26	0.33
	Other expenses	20.11	3.19	0.85	23.30	5.07	8.72
	Total Expenses (IV)	1,023.12	6.11	174.69	1,029.23	219.74	531.01
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	17.08	(4.11)	1.17	12.98	(6.12)	17.04
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Tax (V-VI)	17.08	(4.11)	1.17	12.98	(6.12)	17.04
VIII.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	2.66
	(2) Deferred Tax	-	-	-	-	-	11.09
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	17.08	(4.11)	1.17	12.98	(6.12)	3.29
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	17.08	(4.11)	1.17	12.98	(6.12)	3.29
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	17.08	(4.11)	1.17	12.98	(6.12)	3.29
XVI.	Earnings per Equity Share						
	(1) Basic	0.99	(0.24)	0.07	0.75	(0.35)	0.19
	(2) Diluted	0.99	(0.24)	0.07	0.75	(0.35)	0.19
XVII.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59




For Sarda Proteins Limited

Director

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2020

Rs in Lakhs

Particulars	Six Months ended		Year ended
	30.09.2020	30.09.2019	31.03.2020
	(Un-Audited)	(Un-Audited)	(Audited)
A. ASSETS			
1. Non-Current Assets			
a) Property, Plant and Equipment	0.43	0.65	0.59
b) Capital work in progress	-	-	-
c) Investment Property	-	-	-
d) Goodwill	-	-	-
e) Other Intangible Assets	-	-	-
f) Intangible Assets under Development	-	-	-
g) Biological Assets other than bearer plants	-	-	-
h) Financial Assets	-	-	-
i) Investments	0.13	0.13	0.13
ii) Trade Receivables	-	-	-
iii) Loans	0.01	-	0.01
j) Deferred Tax Assets (net)	29.82	40.92	29.82
k) Other non-current Assets	0.21	0.21	0.21
2. Current Assets			
a) Inventories	-	-	-
b) Financial Assets	-	-	-
i) Investments	-	-	-
ii) Trade Receivables	97.11	243.92	83.45
iii) Cash and Cash Equivalents	0.03	0.25	10.24
iv) Bank Balances and other than (iii) above	4.66	3.65	-
v) Loans	95.24	95.38	90.69
v) Others	-	0.01	-
c) Current Tax Assets (net)	-	-	-
d) Other Current Assets	-	-	-
Total Assets	227.64	385.12	215.14
B. EQUITY AND LIABILITIES			
1. Equity			
a) Equity Share Capital	250.45	250.45	250.45
b) Other Equity	(27.54)	(43.50)	(40.52)
2. Liabilities			
Non current Liabilities			
a) Financial Liabilities			
i) Borrowings	-	-	-
ii) Trade Payables	-	-	-
A) Total Outstanding dues to MSEs	-	-	-
B) Total Outstanding dues to Creditors other than MSEs	-	-	-
iii) Other Financial Liabilities	-	-	-
b) Provisions	1.01	9.34	1.01
c) Deferred Tax Liabilities (net)	-	-	-
d) Other Non Current Liabilities	-	-	-
Current Liabilities			
a) Financial Liabilities			
i) Borrowings	-	-	-
ii) Trade Payables	-	-	-
A) Total Outstanding dues to MSEs	-	-	-
B) Total Outstanding dues to Creditors other than MSEs	0.03	0.38	-
iii) Other Financial Liabilities	-	-	-
b) Other Current Liabilities	1.66	-	4.20
c) Provisions	2.31	-	-
d) Current Tax Liabilities (net)	(0.28)	-	-
Total Equity and Liabilities	227.64	216.67	215.14



For Sarda Proteins Limited

Director

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2020

Rs in Lakhs

Particulars	Six Months ended		Year ended
	30.09.2020 (Un-Audited)	30.09.2019 (Un-Audited)	31.03.2020 (Audited)
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before Tax and Extraordinary Items	12.98	(6.12)	17.05
A. ADJUSTMENT FOR			
Depreciation	0.16	0.26	0.33
Interest Received	(4.02)	(0.10)	(8.02)
Profit on Sale of Investment	-	-	-
Dividend	-	-	-
(Profit) / Loss on sale of Fixed Assets	-	0.03	0.01
Interest Paid	0.01	0.04	0.21
Operating Profit/(Loss) before Working Capital Charges	9.13	(5.90)	9.59
ADJUSTMENT FOR			
Trade and other Receivables	(13.66)	(169.77)	(4.66)
Inventories	-	-	-
Trade & other Payables	(0.48)	171.75	(6.90)
Cash Generated from Operations	(5.01)	(3.92)	(1.98)
Direct Taxes Paid	-	-	2.66
Net Cash from Operating Activities	(5.01)	(3.92)	(4.64)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital Expenditure	-	-	-
Sale of Fixed Assets	-	0.83	0.84
Profit/ (Loss) on sale of Fixed Assets	-	(0.03)	-
Profit on sale of Investment	-	-	-
Sale of Investment	-	-	-
Interest Received	4.02	0.10	8.02
Dividend Received	-	-	-
Net Cash Received from Investing Activities	4.02	0.90	8.86
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Long Term Borrowings	(4.55)	-	-
Proceeds from Short Term Borrowings	-	-	(0.73)
Interest Paid	(0.01)	(0.04)	(0.21)
Net Cash Inflow/ (Outflow) from Financing Activities	(4.56)	(0.04)	(0.94)
Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(5.55)	(3.06)	3.28
Cash & Cash Equivalents (Opening)	10.24	6.96	6.96
Cash & Cash Equivalents (Closing)	4.69	3.90	10.24

Notes:


- The above results were approved by Audit Committee and Board of Directors in their meeting held on 09th November 2020.
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 30-Sep-2020 nor any pending as on 01-Oct-2020.

For and on behalf of the Board
Sarda Proteins Ltd

For Sarda Proteins Limited

Place: Jaipur
Date : 09-Nov-2020

Deepak Datta (DIN: 01672415) Director
Managing Director





Khetawat Agarwal & Co.
Chartered Accountants

Limited Review Report
Unaudited Standalone Quarterly and Half Yearly Results


To
The Board of Directors
Sarda Proteins Ltd.


We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Half year ended on 30th September 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co.
Chartered Accountants
FRN: 003960C


M.L. Agarwal
Partner
M. No.: 072854



UDIN : 20072854AAACL6163

Place : Jaipur
Date : 09.11.2020

Office: 103, 1st Floor, City Centre, Ashok Circle, Alwar - 301001 (Rajasthan)
Phone : Office 0144-2340924, 7014347644
Mobile: 9414215353 (ML Agarwal)
E-mail : khetawatagarwal21@gmail.com